In 2009, through the American Recovery and Reinvestment Act (ARRA), NINDS funded three consortia, to develop well characterized, publically available, induced pluripotent stem cell (iPSC) lines for familial forms of Parkinson’s disease (PD), Huntington’s disease (HD) and Amyotrophic Lateral Sclerosis (ALS). Because of the short two year time period for the development of these resources, NINDS organized a meeting with consortia investigators and interested non-profit organizations and industry representatives to facilitate the sharing of strategies, resources, technologies, and analyses across consortia.
Margaret Sutherland, Ph.D.
National Institute of Neurological Disorders and Stroke
Phone: (301) 496-5680
Last Modified October 18, 2015